BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1161 related articles for article (PubMed ID: 26023239)

  • 1. Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma.
    Makinoshima H; Takita M; Saruwatari K; Umemura S; Obata Y; Ishii G; Matsumoto S; Sugiyama E; Ochiai A; Abe R; Goto K; Esumi H; Tsuchihara K
    J Biol Chem; 2015 Jul; 290(28):17495-504. PubMed ID: 26023239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor (EGFR) signaling regulates global metabolic pathways in EGFR-mutated lung adenocarcinoma.
    Makinoshima H; Takita M; Matsumoto S; Yagishita A; Owada S; Esumi H; Tsuchihara K
    J Biol Chem; 2014 Jul; 289(30):20813-23. PubMed ID: 24928511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
    Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
    Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PTPRH promotes the progression of non-small cell lung cancer via glycolysis mediated by the PI3K/AKT/mTOR signaling pathway.
    Wang S; Cheng Z; Cui Y; Xu S; Luan Q; Jing S; Du B; Li X; Li Y
    J Transl Med; 2023 Nov; 21(1):819. PubMed ID: 37974250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevation of CD109 promotes metastasis and drug resistance in lung cancer via activation of EGFR-AKT-mTOR signaling.
    Lee KY; Shueng PW; Chou CM; Lin BX; Lin MH; Kuo DY; Tsai IL; Wu SM; Lin CW
    Cancer Sci; 2020 May; 111(5):1652-1662. PubMed ID: 32133706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
    Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
    J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxysafflor Yellow A Promotes HaCaT Cell Proliferation and Migration by Regulating HBEGF/EGFR and PI3K/AKT Pathways and Circ_0084443.
    Zhang Y; Xiao YW; Ma JX; Wang AX
    Chin J Integr Med; 2024 Mar; 30(3):213-221. PubMed ID: 37688744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synaptotagmin 12 (SYT12) Gene Expression Promotes Cell Proliferation and Progression of Lung Adenocarcinoma and Involves the Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
    Liu K; Luo J; Shao C; Ren Z; Sun S; Zhu Y; Zhou H; Jiang Z; Li X; Gu W; Xu Y; Qiang Y; Ren B; Xu L; Wu H; Shen Y
    Med Sci Monit; 2020 Feb; 26():e920351. PubMed ID: 32108133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
    Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
    J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of orexin A on glucose metabolism in human hepatocellular carcinoma in vitro via PI3K/Akt/mTOR-dependent and -independent mechanism.
    Liu Y; Zhao Y; Guo L
    Mol Cell Endocrinol; 2016 Jan; 420():208-16. PubMed ID: 26549689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
    Gong T; Cui L; Wang H; Wang H; Han N
    J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knockdown of lysine (K)-specific demethylase 2B KDM2B inhibits glycolysis and induces autophagy in lung squamous cell carcinoma cells by regulating the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway.
    Xie Z; Li H; Zang J
    Bioengineered; 2021 Dec; 12(2):12227-12235. PubMed ID: 34783291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular entry of human papillomavirus type 16 involves activation of the phosphatidylinositol 3-kinase/Akt/mTOR pathway and inhibition of autophagy.
    Surviladze Z; Sterk RT; DeHaro SA; Ozbun MA
    J Virol; 2013 Mar; 87(5):2508-17. PubMed ID: 23255786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orexin A affects HepG2 human hepatocellular carcinoma cells glucose metabolism via HIF-1α-dependent and -independent mechanism.
    Wan X; Liu Y; Zhao Y; Sun X; Fan D; Guo L
    PLoS One; 2017; 12(9):e0184213. PubMed ID: 28886081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mRNA expression of programmed cell death ligand 1 and components of the phosphatidylinositol 3-kinase/AKT/phosphatase and tensin homolog pathway in epidermal growth factor receptor mutation-positive lung adenocarcinoma.
    Han K; Zhang Y
    J Cancer Res Ther; 2019; 15(4):914-920. PubMed ID: 31436252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic activation of the PI3K/Akt pathway promotes cellular glucose uptake by downregulating the expression of thioredoxin-interacting protein.
    Hong SY; Yu FX; Luo Y; Hagen T
    Cell Signal; 2016 May; 28(5):377-383. PubMed ID: 26826652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
    Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
    Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lung cancer cells that survive ionizing radiation show increased integrin α2β1- and EGFR-dependent invasiveness.
    Li X; Ishihara S; Yasuda M; Nishioka T; Mizutani T; Ishikawa M; Kawabata K; Shirato H; Haga H
    PLoS One; 2013; 8(8):e70905. PubMed ID: 23951036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTOR-Rictor-EGFR axis in oncogenesis and diagnosis of glioblastoma multiforme.
    Ramaiah MJ; Kumar KR
    Mol Biol Rep; 2021 May; 48(5):4813-4835. PubMed ID: 34132942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
    Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.